Benign prostatic hyperplasia: pathophysiology and pharmacological treatment
Recent studies have confirmed that a-blocker therapy and antihormonal therapy are effective and safe treatment modalities in patients with symptomatic benign prostatic hyperplasia. New data suggest that the clinical response to medical therapy lasts for at least 3 years without any increase in side...
Gespeichert in:
| Veröffentlicht in: | Current opinion in nephrology and hypertension 1995-09, Vol.4 (5), p.455-459 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 5 |
| container_start_page | 455 |
| container_title | Current opinion in nephrology and hypertension |
| container_volume | 4 |
| creator | Madsen, Finn A Bruskewitz, Reginald C |
| description | Recent studies have confirmed that a-blocker therapy and antihormonal therapy are effective and safe treatment modalities in patients with symptomatic benign prostatic hyperplasia. New data suggest that the clinical response to medical therapy lasts for at least 3 years without any increase in side effects during this period. |
| doi_str_mv | 10.1097/00041552-199509000-00015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77661522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77661522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2705-774d15590a27f0fd2c943e7f5edfbac4f79f803446e882111304b8a04fbfae913</originalsourceid><addsrcrecordid>eNp1kU1PAyEQhonRVK3-BJM9eVsFFpZdb2r8ik286JlMd4fuKvsh0DT991Jbe_NAYJh3Zl4eCEkYvWK0VNeUUsGk5CkrS0nLGKZxMXlATphQWZpLkR3GM815KgrOjsmp959RkgkmJmRSyFwIyU_I6x327aJPRjf4AKGtkmY9ohst-BZukhFCM4zN2reDHRbrBPo6GRtwHVSbi7YCmwSHEDrswxk5MmA9nu_2Kfl4fHi_f05nb08v97eztOKKylQpUUfvJQWuDDU1r0qRoTISazOHShhVmiIaFTkW0TpjGRXzAqgwcwNYsmxKLrd9o-nvJfqgu9ZXaC30OCy9VirPmeQ8CoutsIqv8w6NHl3bgVtrRvWGo_7jqPcc9S_HWHqxm7Gcd1jvC3fgYl5s86vBBnT-yy5X6HSDYEOj__ue7Ad99X5I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77661522</pqid></control><display><type>article</type><title>Benign prostatic hyperplasia: pathophysiology and pharmacological treatment</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Madsen, Finn A ; Bruskewitz, Reginald C</creator><creatorcontrib>Madsen, Finn A ; Bruskewitz, Reginald C</creatorcontrib><description>Recent studies have confirmed that a-blocker therapy and antihormonal therapy are effective and safe treatment modalities in patients with symptomatic benign prostatic hyperplasia. New data suggest that the clinical response to medical therapy lasts for at least 3 years without any increase in side effects during this period.</description><identifier>ISSN: 1062-4821</identifier><identifier>EISSN: 1473-6543</identifier><identifier>DOI: 10.1097/00041552-199509000-00015</identifier><identifier>PMID: 8564452</identifier><language>eng</language><publisher>England: Lippincott-Raven Publishers</publisher><subject>Adrenergic alpha-Antagonists - therapeutic use ; Enzyme Inhibitors - therapeutic use ; Finasteride - therapeutic use ; Humans ; Male ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - physiopathology</subject><ispartof>Current opinion in nephrology and hypertension, 1995-09, Vol.4 (5), p.455-459</ispartof><rights>Lippincott-Raven Publishers.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2705-774d15590a27f0fd2c943e7f5edfbac4f79f803446e882111304b8a04fbfae913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8564452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Madsen, Finn A</creatorcontrib><creatorcontrib>Bruskewitz, Reginald C</creatorcontrib><title>Benign prostatic hyperplasia: pathophysiology and pharmacological treatment</title><title>Current opinion in nephrology and hypertension</title><addtitle>Curr Opin Nephrol Hypertens</addtitle><description>Recent studies have confirmed that a-blocker therapy and antihormonal therapy are effective and safe treatment modalities in patients with symptomatic benign prostatic hyperplasia. New data suggest that the clinical response to medical therapy lasts for at least 3 years without any increase in side effects during this period.</description><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Finasteride - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - physiopathology</subject><issn>1062-4821</issn><issn>1473-6543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1PAyEQhonRVK3-BJM9eVsFFpZdb2r8ik286JlMd4fuKvsh0DT991Jbe_NAYJh3Zl4eCEkYvWK0VNeUUsGk5CkrS0nLGKZxMXlATphQWZpLkR3GM815KgrOjsmp959RkgkmJmRSyFwIyU_I6x327aJPRjf4AKGtkmY9ohst-BZukhFCM4zN2reDHRbrBPo6GRtwHVSbi7YCmwSHEDrswxk5MmA9nu_2Kfl4fHi_f05nb08v97eztOKKylQpUUfvJQWuDDU1r0qRoTISazOHShhVmiIaFTkW0TpjGRXzAqgwcwNYsmxKLrd9o-nvJfqgu9ZXaC30OCy9VirPmeQ8CoutsIqv8w6NHl3bgVtrRvWGo_7jqPcc9S_HWHqxm7Gcd1jvC3fgYl5s86vBBnT-yy5X6HSDYEOj__ue7Ad99X5I</recordid><startdate>199509</startdate><enddate>199509</enddate><creator>Madsen, Finn A</creator><creator>Bruskewitz, Reginald C</creator><general>Lippincott-Raven Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199509</creationdate><title>Benign prostatic hyperplasia: pathophysiology and pharmacological treatment</title><author>Madsen, Finn A ; Bruskewitz, Reginald C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2705-774d15590a27f0fd2c943e7f5edfbac4f79f803446e882111304b8a04fbfae913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Finasteride - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Madsen, Finn A</creatorcontrib><creatorcontrib>Bruskewitz, Reginald C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in nephrology and hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Madsen, Finn A</au><au>Bruskewitz, Reginald C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benign prostatic hyperplasia: pathophysiology and pharmacological treatment</atitle><jtitle>Current opinion in nephrology and hypertension</jtitle><addtitle>Curr Opin Nephrol Hypertens</addtitle><date>1995-09</date><risdate>1995</risdate><volume>4</volume><issue>5</issue><spage>455</spage><epage>459</epage><pages>455-459</pages><issn>1062-4821</issn><eissn>1473-6543</eissn><abstract>Recent studies have confirmed that a-blocker therapy and antihormonal therapy are effective and safe treatment modalities in patients with symptomatic benign prostatic hyperplasia. New data suggest that the clinical response to medical therapy lasts for at least 3 years without any increase in side effects during this period.</abstract><cop>England</cop><pub>Lippincott-Raven Publishers</pub><pmid>8564452</pmid><doi>10.1097/00041552-199509000-00015</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1062-4821 |
| ispartof | Current opinion in nephrology and hypertension, 1995-09, Vol.4 (5), p.455-459 |
| issn | 1062-4821 1473-6543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77661522 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adrenergic alpha-Antagonists - therapeutic use Enzyme Inhibitors - therapeutic use Finasteride - therapeutic use Humans Male Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - physiopathology |
| title | Benign prostatic hyperplasia: pathophysiology and pharmacological treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A03%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benign%20prostatic%20hyperplasia:%20pathophysiology%20and%20pharmacological%20treatment&rft.jtitle=Current%20opinion%20in%20nephrology%20and%20hypertension&rft.au=Madsen,%20Finn%20A&rft.date=1995-09&rft.volume=4&rft.issue=5&rft.spage=455&rft.epage=459&rft.pages=455-459&rft.issn=1062-4821&rft.eissn=1473-6543&rft_id=info:doi/10.1097/00041552-199509000-00015&rft_dat=%3Cproquest_cross%3E77661522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77661522&rft_id=info:pmid/8564452&rfr_iscdi=true |